292 related articles for article (PubMed ID: 34350060)
21. Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.
Li P; Chai J; Chen Z; Liu Y; Wei J; Liu Y; Zhao D; Ma J; Wang K; Li X; Shao Y; Gong L; Zhang W; Guo S; Yan Q; Li M; Fan L; Wang Z
Front Oncol; 2021; 11():622648. PubMed ID: 33747936
[TBL] [Abstract][Full Text] [Related]
22. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
23. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
24. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.
Almasmoum HA
J Appl Genet; 2024 Feb; 65(1):57-72. PubMed ID: 38001281
[TBL] [Abstract][Full Text] [Related]
25. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
26. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
27. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
28.
Dobashi A; Togashi Y; Tanaka N; Yokoyama M; Tsuyama N; Baba S; Mori S; Hatake K; Yamaguchi T; Noda T; Takeuchi K
Oncotarget; 2018 Apr; 9(28):19555-19568. PubMed ID: 29731965
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
30. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
31. New murine models of aggressive lymphoma.
Flümann R; Nieper P; Reinhardt HC; Knittel G
Leuk Lymphoma; 2020 Apr; 61(4):788-798. PubMed ID: 31752573
[TBL] [Abstract][Full Text] [Related]
32. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
[No Abstract] [Full Text] [Related]
33. Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis.
Lv L; Qi X; Wang C; Ma Y; Nie Y; Abulaiti R; Zhang F; Shi Q; Kou Z; Abuduer M; Zhai S; An L; Huang Q; Gu Z; Ou Q; Liu H; Wang Z; Shao Y; Sun Z; Fu L; Wang X; Mao M; Li Y
Clin Exp Med; 2023 Oct; 23(6):2675-2685. PubMed ID: 36811800
[TBL] [Abstract][Full Text] [Related]
34. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
[TBL] [Abstract][Full Text] [Related]
35. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
36. Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
Asmar F; Hother C; Kulosman G; Treppendahl MB; Nielsen HM; Ralfkiaer U; Pedersen A; Møller MB; Ralfkiaer E; de Nully Brown P; Grønbæk K
Oncotarget; 2014 Apr; 5(7):1912-25. PubMed ID: 24722400
[TBL] [Abstract][Full Text] [Related]
37. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
38. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
39. Influence of
Porpaczy E; Wohlfarth P; Königsbrügge O; Rabitsch W; Skrabs C; Staber P; Worel N; Müllauer L; Simonitsch-Klupp I; Kornauth C; Rohrbeck J; Jaeger U; Schiefer AI
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830747
[TBL] [Abstract][Full Text] [Related]
40. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
Li Q; Huang J; Ou Y; Li Y; Wu Y
Immunotherapy; 2019 Mar; 11(4):265-272. PubMed ID: 30606076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
